Rochester, Minnesota 55905

  • Healthy

Purpose:

An objective measure of treatment response could be a valuable new tool in the armamentarium of depression management, and this holds true for stimulation-based and pharmacological therapies alike. Hence, the Medibio Depression Monitoring Study will use the Medibio analytics platform to characterize autonomic, circadian, and sleep patterns before and during the initial 8 weeks of pharmacologic therapy for moderate-to-severe depression. The study will also explore any differences in these measures between treatment responders and non-responders, and between depression subtypes, including bipolar and unipolar depression. The study will also characterize longitudinal, ambulatory EEG measures throughout the observation period.


Study summary:

This longitudinal, two-phase, three-arm, exploratory, observational study will use the Medibio analytics platform—with heart rate, activity, postural, and EEG data inputs—to characterize autonomic, circadian, and sleep patterns in unipolar depressed and bipolar depressed patients, which will include those with atypical and melancholic subtypes, undergoing the initial phase of standard pharmacological treatment, as well as in a non-depressed control group. Phase I will serve as a non-blinded, discovery phase for Medibio algorithm development. Phase II is optional, based upon sponsor/investigator assessment of results from Phase I. Phase II procedures will be identical to those in Phase I, with the exception that the Medibio algorithm will be blinded to clinical classification and status. The study cohorts will comprise: a) individuals initiating standard pharmacologic therapy with SSRIs for moderate-to- severe unipolar depression (will include subjects with melancholic and atypical subtypes), b) individuals initiating standard pharmacologic therapy with lamotrigine, lithium, or valproate for moderate or severe bipolar I or II depression (will also include subjects with melancholic and atypical subtypes), and c) non-depressed individuals who have been matched at the group level for age and gender (control subjects). Before the commencement of pharmacologic therapy (Baseline, t=0), at t=4 weeks, and at t=8 weeks, heart rate, activity, postural data will be collected using the Zephyr BioPatch (Medtronic, Inc.) and ambulatory EEG data will be collected using the ZMachine Insight (General Sleep Corp). Recordings at each time point will consist of three 24-hour Zephyr recordings and three overnight ZMachine recordings. Clinical assessments will also be captured at the same time points, comprising both clinician-administered instruments [Clinical Global Impression (CGI), Hamilton Depression Rating Scale-17 (HAMD-17), and Young Mania Rating Scale (YMRS)] and subject self-rated instruments [Patient Health Questionnaire-9 (PHQ-9) and Quick Inventory of Depressive Symptomatology-Self Report (QIDS SR16)]. Zephyr and ZMachine data will be filtered based on quality (duration and completeness) and may be 'de-noised,' then will be processed by the Medibio platform to generate autonomic, circadian, and sleep metrics for use in the statistical analysis of study results.


Criteria:

Inclusion Criteria: - Subject is willing and able to provide consent. - Subject has ability to read and understand the instructions for the study. - Subject is willing to adhere to study procedures. Exclusion Criteria: 1. Subject has presence of mild, moderate, or severe Major Depressive Disorder Episode, based on DSM-IV criteria for diagnosis as documented by clinician administered M.I.N.I OR HAMD-17 rating scale score >7. 2. Subject has bipolar disorder. 3. Subject has active psychotic symptoms. 4. Subject has known or is suspected to have a personality disorder. 5. Subject has current suicidality of medium or high risk as determined by M.I.N.I. or HAMD-17 item #3 score of 3 of higher. 6. Subject has history of central or obstructive sleep apnea OR has a STOP-BANG score of ≥5 OR has a Home Sleep Test assessment (ApneaLink, ResMed) demonstrating AHI≥15. 7. Subject has a pacemaker. 8. Subject currently uses benzodiazepines, sedative-hypnotics, or trazadone on a scheduled basis OR will be likely be prescribed such medication during the 8-week observational phase of the study. 9. Subject currently uses antipsychotic medication for any indication OR will be likely be prescribed such medication during the 8-week observational phase of the study. 10. Subject currently uses chronotropic medication, such as beta-blockers, digoxin, sinoatrial/atrioventricular nodal-acting calcium channel blockers, and amiodarone. 11. Subject is suspected or known to have active alcohol or drug abuse (including but not limited to abuse of marijuana). 12. Subject has a terminal illness. 13. For female subjects, subject is currently known to be pregnant or lactating. 14. Subject has any other acute or chronic condition that in the investigators opinion would preclude the subject from being able to meet all of the protocol requirements, or would compromise the subject's safety during participation in the study, as judged by the investigator. 15. Subject is currently participating in another clinical study, or participated in a clinical study in the past 30 days during which an investigational device or drug was used.


NCT ID:

NCT03538275


Primary Contact:

Francoise Mercadier-Crevel, Pharm.D.
Phone: +19222220551
Email: francoise.mercadier.crevel@medibio.com.au


Backup Contact:

Email: archie.defillo@medibio.com.au
Archie Defillo, MD
Phone: +1952 847 3552


Location Contact:

Rochester, Minnesota 55905
United States

Mark A Frye, MD
Phone: 507-538-3270
Email: MFrye@mayo.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: June 28, 2022

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.